STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
Form 4 overview: On 06/18/2025 STAAR Surgical Co. (STAA) granted Director Arthur C. Butcher equity under its 2025-2026 non-employee director compensation program.
- Restricted Stock Units (RSUs): 5,341 units acquired at $0. Each RSU converts into one common share when vested. Vesting occurs in full on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting.
- Stock options: 9,708 options with a $16.85 exercise price. Options vest 18 Jun 2026 and expire 17 Jun 2035.
No dispositions were reported; all transactions are coded “A” (acquisition). Ownership is listed as direct, indicating the director holds the awards personally. The filing is routine compensation disclosure and does not contain earnings or operational data.
STAAR Surgical Co. (STAA) – Form 4 insider filing
On 18 June 2025, non-employee director Dr. Elizabeth Yeu received her annual board equity package:
- Restricted Stock Units (RSUs): 5,341 – each RSU converts to one common share upon vesting.
- Stock Options: 9,708 – exercise price $16.85, expire 17 June 2035.
On 18 June 2025, STAAR Surgical Company (STAA) convened its 2025 Annual Meeting of Shareholders with a strong quorum of 44,746,693 shares (≈90% of the 49.5 million outstanding).
Director elections (Proposal 1): All six nominees were re-elected for terms expiring at the 2026 meeting. Shareholder support ranged from 96%–99% of votes cast, with Arthur C. Butcher receiving 41.1 million “For” votes and Lilian Y. Zhou receiving 41.9 million.
Auditor ratification (Proposal 2): BDO USA, P.C. was confirmed as independent auditor for fiscal 2025 with 44,463,071 “For” votes (≈99%), only 273,085 “Against,” and 10,537 abstentions.
Say-on-Pay advisory vote (Proposal 3): Compensation of named executive officers was approved on a non-binding basis, receiving 41,130,690 “For” votes (≈97.5%), 1,049,897 “Against,” 24,667 abstentions, and 2,541,439 broker non-votes.
No other matters were brought before the meeting, and no substantive changes to corporate strategy or financial guidance were disclosed.